arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Outlook Therapeutics, Inc.

OTLK
$1.02 ▲ +0.05 (+5.29%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
46 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
59
Health
Fair
Bullish
auto_awesome

Analytical Summary

Outlook Therapeutics, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $83.5M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC 38.2%
FCF / Share $-0.10
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

46-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$-91.79K
↓ -106.1%
Net Income Profit after all expenses
$-23.06M
— 0.0%
Operating Margin Operating profit as % of sales
-216.8%
↑ +47.4%
FCF / Share Free cash flow per share
$-0.10
↑ +61.5%
Long-Term Debt Long-term obligations
$967.05M
↑ +1538424.6%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
100
Financial Health
9
Cash Quality
56

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 12 years · 46 quarters